FindTrial
Sign In

The safety study of autologous blood recovery technology in tumor surgery

The safety study of autologous blood recovery technology in tumor surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016162
Enrollment
Unknown
Registered
2018-05-16
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumor

Interventions

Case series:Intra-operative cell salvage combined with leukocyte depletion filter

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: patients with spinal tumors and renal cancer with inferior vena cava tumor emboli

Exclusion criteria

Exclusion criteria: 1. patients deny; 2. Patients with signs of infection such as interleukin increased and fever; 3. mental disease; 4. Rh-negative blood.

Design outcomes

Primary

MeasureTime frame
number of tumor cells;—

Countries

China

Contacts

Public ContactXiangyang Guo

Peking University Third Hospital

puthmzk@163.com+86 13581961965

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026